MedinCell demonstrates in vivo the efficacy of the first injectable combining surgical anesthesia and 3 days opioid free postoperative pain management March 11, 2019 March 11, 2019
MedinCell receives funding for the second formulation phase of its 6-month injectable contraceptive January 24, 2019 January 24, 2019
Publication of the activity report and financial information for the first half-year (April – Sept. 2018) December 3, 2018 December 3, 2018
Publication of the activity report and financial information for the first half-year on December 3, 2018 November 27, 2018 November 27, 2018
Partial exercise of the over-allotment option – Final amount of the share issue increased to €31.4m November 5, 2018 November 5, 2018
MedinCell announces the extension of the subscription period for the shares offered as part of its initial public offering September 25, 2018 September 25, 2018
MedinCell launches its initial public offering on the regulated market of Euronext in Paris September 17, 2018 September 17, 2018
MedinCell announces filing of its document de base with the AMF, the first step towards its planned IPO on the regulated market of Euronext in Paris September 5, 2018 September 5, 2018
